Drug intelligence / Profile preview

aCell Inj.

Development stage: Unknown
Lead developer: Asia Cell Therapeutics
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

aCell Inj. is an investigational allogeneic cell therapy consisting of human umbilical cord-derived mesenchymal stem cells (UC-MSCs), developed by Asia Cell Therapeutics. It is primarily being evaluated for the treatment of mild to moderate acute respiratory distress syndrome (ARDS). The therapy works through paracrine signaling and immunomodulatory mechanisms, exerting anti-inflammatory effects, regulating the immune response, and promoting tissue repair in the lungs. It is administered via intravenous infusion and is currently in Phase 2 clinical development in China under approval from the National Medical Products Administration (NMPA).

Other names: human umbilical cord mesenchymal stem cellsAllogenic Umbilical-Cord Mesenchymal Stem Cell Intravenous InjectionUC-MSCsUCMSC

Beyond the preview

Go deeper on aCell Inj..

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aCell Inj..

Explore the full profile